Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2013
Price :
$35
*
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 01 Jan 2013 Results published in the Neuropharmacology.
- 07 Nov 2012 Actual initiation date changed from 1 Oct 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 16 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.